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ABSTRACT 
Objective: The present work describes stability indicating (SI) RP-HPLC-PDA method for determination of abiraterone acetate (ABA) and 
characterization of its base catalyzed degradation product by LC-MS. 
Methods: The separation was achieved by using column Kromasil C18 
Results: The retention time of ABA was 5.4±0.01 min. Linearity was found to be in the range of 5–30 μg/ml. The limit of detection and quantitation 
were 0.25 μg/ml and 0.75 μg/ml respectively, and percentage recovery of ABA was found to be 99.52 to 100.13 %. Mass spectral data of base 
degraded product of ABA shows a prominent molecular ion peak at m/z-391.5. Major fragmentation leads to formation of 10–Methyl 
2,3,4,7,8,9,10,11,12,13,14,15-dodecanhydro-1H cyclopenta (α)phenanthren-3-ol as a degradant (D
(250 mm × 4.6 mm, 4.0 µ) using acetonitrile (ACN): ammonium acetate buffer 
10 mM, pH adjusted to 3.5 with acetic acid (AA) in the ratio of 10:90 % v/v as eluent. The Mobile phase flow rate was 0.6 ml/min and data 
integration was achieved at 235 nm. 
2) at m/z-257.81, due to corresponding loss of 
C8H12
Conclusion: The results of the various validation studies showed that the LC method is fast, specific, accurate, reproducible, possessed significant 
linearity and precision. The drug was found to be stable under all the stress conditions except basic stress. Thus developed method reported first 
time is novel with a very short run time of 6 min. 
ON. All the analytical validation parameters were determined and found in the limit as per ICH guidelines. 
Keywords: Abiraterone acetate, HPLC, Stability indicating assay, Forced degradation, Validation, LC-MS. 
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INTRODUCTION 
ABA is chemically (3B 17-(3-Pyridinyl) androsta-5, 16 dien-3yl 
acetate) (fig. 1), is an antineoplastic agent with an orally active 
inhibitor of the steroidal enzyme CYP17A1. CYP17A1 is an enzyme 
that catalyzes the biosynthesis of androgen and is highly expressed 
in adrenal, testicular and prostatic tumor tissue. USFDA approved 
this compound in dec 2012 and currently marketed for the 
treatment of patients with metastatic castration-resistant prostate 
cancer 
 
(CRPC), which is a serious and aggressive type of prostate 
cancers [1]. 
 
Fig. 1: Chemical structure of ABA 
 
Review of literature for ABA reveals that there are few analytical 
methods reported for its determination. LC/MS/MS-ESI method is 
used for its determination in rat and human plasma [2]. But no 
article related to the stability indicating a chromatographic method 
for determination of the ABA by predicting possible degradation 
pathways has been reported. The International Conference on 
Harmonization (ICH) guideline entitled ‘stability testing of new drug 
substances and products’ requires the stress testing to be carried 
out to elucidate the inherent stability characteristics of the active 
substance [3]. An ideal stability indicating method is one that 
quantifies the standard drug alone and also resolves its degradation 
products. Since HPLC is a routine analytical technique used due to its 
advantage of higher sensitivity, this technique was selected for 
stability indicating assay. The aim of the present work is to develop 
a fast, accurate, specific, and reproducible SI RP-HPLC-PDA method 
for determination of ABA in the presence of degradation products 
formed under different stress conditions and the characterization of 
base induced degradation product by LC-MS. 
MATERIALS AND METHODS 
Chemicals and reagents 
Active Pharmaceutical ingredient (API) of ABA (purity 98.84 %) was 
received as gift sample from Sun Pharmaceuticals Ltd., Ahmednagar. 
The pharmaceutical tablet dosage form formulated in Laboratory 
was used in this study. HPLC Grade Methanol and ACN were 
supplied by Merck Specialties Pvt. Ltd., Mumbai. Analytical grade 
acetic acid (AA) was supplied by Labin Chemicals Pune. Analytical 
grade ammonium acetate was supplied by Analab Fine Chemicals 
Pvt. Ltd., Mumbai. Double distilled water prepared in the laboratory 
was used for the study. 
Instrumentation and chromatography conditions 
The chromatographic separation was performed on a Waters Binary 
gradient HPLC system, Japan, with the automatic injection facility 
was employed for this work. The detector consists of a Waters 2998 
Photodiode Array Detector (PDA) and operated at 254 nm. The 
software used was Empower 2. The column used was Kromasil C18 
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Preparation of standard and sample solution 
Column (250 mm × 4.6 mm, 4.0 µ). Chromatographic analysis was 
carried out at 40 °C temperature. The drug and degradation 
products were separated with a mobile phase consisting of ACN: 
ammonium acetate buffer 10 mM pH-3.5 (adjusted using AA). The 
mobile phase was sonicated and filtered through 25 mm, 0.45 μ 
nylon membrane filter. The flow rate was 0.6 ml/min, injection 
volume was 30 μl. 
A standard stock solution of ABA was prepared by dissolving and 
diluting 100 mg of the drug to 100 ml with ACN. Aliquots from this 
solution were suitably diluted with mobile phase to get the working 
standard solutions of ABA in the concentration range of 5–30 μg/ml 
with the mobile phase. For the preparation of sample solution, 
twenty tablets were weighed and finely powdered. An accurately 
weighed tablet powder according to label claim equivalent 100 mg 
was accurately weighed and transferred into a 100 ml volumetric 
flask containing 80 ml of ACN and sonicated for 20 min. This 
solution was further diluted to get final concentration15 μg/ml. The 
solution was filtered through 25 mm 0.45 μ nylon membrane filter. 
The resulting solution was injected into the column and peak area 
was recorded for quantitation. 
Validation of RP-HPLC method 
The method was validated using standard sample of ABA with the 
label claim of 250 mg by the determination of specificity, linearity and 
range, precision, accuracy, limit of detection, limit of quantification and 
robustness following ICH method validation guidelines [4]. 
System suitability 
The system suitability test was performed to ensure that the 
complete testing system was suitable for the intended application. A 
standard solution containing 15 μg/ml of ABA was injected six times. 
The parameters measured were peak area, retention time, 
theoretical plates and tailing factor. 
Linearity 
Linearity test solutions were prepared by diluting a standard stock 
solution of ABA at concentration levels of 5-30 μg/ml. The solutions 
were injected six times and six curves were constructed. The slope 
and intercept were calculated. 
Accuracy 
Accuracy was carried out by selecting a drug concentration to 80, 
100, and 120 % of label claim were present. At each level three 
determinations were carried out and the results obtained were 
compared with expected results. 
Precision 
The precision of the method was verified by intraday and 
intermediate precision studies. The intraday precision of the method 
was checked by analyzing test solution 10, 15 and 20 μg/ml of ABA 
which three times. The intermediate precision of the method was 
checked by repeating assay of 10, 15, 20 μg/ml of ABA three times in 
three sequential days. The intraday and intermediate precision of 
sample applications and measurement of peak area for the drug 
were expressed in terms of % relative standard deviation (% RSD). 
Specificity 
Specificity is the ability of the method to determine the analyte 
response in the presence of its potential impurity. The stability 
indicating the capability of the method was established from the 
peak purity of ABA in the degraded sample. Forced degradation 
studies of the drug substance can help to identify the likely 
degradation products which can assist to establish the degradation 
pathways and the stability of the molecule. ABA was degraded under 
different stress conditions like acidic, alkaline, oxidative hydrolysis, 
UV light, dry heat and neutral conditions [5]. 
a. Acid degradation studies 
To 5 ml of stock solution, 5 ml of 1M hydrochloric acid was added 
and solution kept aside for 5 h. at 45 °C. The resultant solution was 
suitably diluted to obtain final conc. of 15μg/ml. 30μl solutions were 
injected into the system, and the chromatograms were recorded to 
assess the stability of the sample. 
b. Base degradation studies 
To 5 ml of stock solution, 5 ml 0.1 M sodium hydroxide was added 
and solution kept aside for 5 h. at 45 o
c. Peroxide degradation studies 
C. The resultant solution was 
suitably diluted to obtain 15 μg/ml. 30 μl solutions were injected 
into the system and the chromatograms were recorded to assess the 
stability of the sample. 
To 5 ml of stock solution, 5 ml of 30 % hydrogen peroxide (H2O2
d. Thermal degradation studies 
) 
was added and the solutions were kept aside for 5 h. at 45 °C and 
resultant solution was suitably diluted to obtain 15 μg/ml. 30 μl 
solutions were injected into the system and the chromatograms 
were recorded to assess the stability of the sample. 
The standard drug solution was placed in the oven at 45 °C for 24 h. 
To study dry heat degradation, the resultant solution was diluted to 
obtain final conc. 15 μg/ml. 30 μl solutions were injected into the 
system and the chromatograms were recorded to assess the stability 
of the sample. 
e. Photostability studies 
The photochemical stability of the drug was also studied by exposing 
the sample solution to UV Light for 12 h. For HPLC study, the 
resultant solution was suitably diluted to obtain final conc. 15 
μg/ml. 30 μl solutions were injected into the system and the 
chromatograms were recorded to assess the stability of the sample 
f. Neutral degradation studies 
Stress testing under neutral conditions was studied by refluxing the 
drug in water for 5 h. at 45 °C. For HPLC study, the resultant solution 
was suitably diluted to obtain 15 μg/ml. 30 μl solutions were 
injected into the system and the chromatograms were recorded to 
assess the stability of the sample. 
Robustness 
The robustness of an analytical procedure refers to its ability to 
remain unaffected by small and deliberate variations in method 
parameter and provides an indication of its reliability for the routine 
analysis. The robustness of the method were determined by 
analyzing a sample by varying parameters such as column 
temperature (40±2 o
LOD and LOQ 
C), flow-rate (0.6±0.1 ml/min), pH (3.5±0.2) 
and wavelength (235±2 nm). 
LOD and LOQ were calculated as per ICH guidelines as 3.3 σ/S and 
10 σ/S, respectively, where σ is the standard deviation and S is the 
average of the slopes of the calibration plots. 
Method stability 
To confirm the stability of standard and tablet sample solutions 
during the analytical process, both solutions were analyzed over a 
period of 3 d at room temperature (25±0.5 °C). 
LC-MS analysis 
The Base induced degradation product was identified using LC-MS 
analysis. To characterize the base degradation products solution 
degraded under basic condition was subjected to LC-MS analysis. LC-
MS studies were performed on thermo scientific LC-MS instrument 
using Agilent, USA (Model No 6460) ZORBAX eclipse plus C18 
column [100 mm (L) x 4.6 mm (D), 2.7 μm]. The flow rate was 0.5 
ml/min and detection was performed using Triple-Quadrupole ESI. 
RESULTS AND DISCUSSION 
In this work an analytical LC method was developed and validated 
for the determination of ABA in bulk drug. To prove the method was 
stability indicating the drug was assayed in the presence of its 
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degradation products obtained under different stress conditions. The 
base degraded product was characterized by mass spectral studies. 
Method development 
In initial trials, different combinations of ACN, methanol, phosphate 
and ammonium acetate buffer were tried. As part of method 
development trial 1 (fig. 2) (T1) with mobile phase methanol: 
phosphate buffer (10 mM) (40:60 % v/v) pH-4.35, at flow rate 1 
ml/min. Using column Kromasil C18 was observed. In this trial 
baseline disturbance was observed and the peak was broad with 
unacceptable tailing. Further changes in flow rate, pH, and mobile 
phase (MP) composition were carried out form observations of 
these trials it was concluded that the mobile phase needs to be 
changed. Therefore, trial 2 was carried out with changes in MP, 
phosphate buffer was replaced with acetate buffer. Trail 2 was 
carried out with MP ACN: ammonium acetate buffer (70:30 % v/v) 
pH-6.2, at a flow rate 1 ml/min on column Kromasil C18. In T2
Therefore, changes in pH and flow rate were carried out. Finally the 
optimized condition for ABA mobile phase consisting of ACN: 10 mM 
Ammonium acetate buffer (10:90 v/v) pH-3.5 (adjusted using AA) at 
a flow rate 0.6 ml/min and injection volume is 30 µl gave a sharp 
peak of ABA and, in conclusion, this system was optimized. It was 
observed that the developed chromatographic condition provides 
better separation of ABA (5.43 min) and its degraded products, 
which also gave a symmetric peak of the compound. The run time 
of the method was 10 min. The % RSD value calculated for the 
peak area was 0.86 %, tailing factor was 1.23 and no. of theoretical 
plates was 3477 [6]. 
 tailing 
was observed and less plate count observed.  
 
 
Fig. 2: Trial 1 (T1), Trial 2 (T2
 
System suitability 
The experimental results showed that the parameters tested were 
within the acceptable range (% RSD<2.0 %) indicating that the 
system was suitable for the analysis intended. Overlay 
chromatogram for system suitability is shown in fig. 3 (a). 
Validation of method 
) and final optimized condition of ABA 
Validation of method was performed as per ICH Quality guidelines 
on validation, analytical procedures (Q2B). 
Linearity 
The developed method was found to be linear at concentrations 
ranging from 5-30 μg/ml of ABA. The calibration curves of the ABA 
were constructed by plotting area response (y) against the 
concentration of drug (x) and typically described by the following 
regression analysis equation: y= 36258x+8239.3, r2
 
= 0.9991. The 
results showed that an excellent correlation existed between peak 
areas and concentration of the drug within the concentration range 
indicated above and confirmed the linearity of the standard curves.
  
(a) (b) 
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Method sensitivity 
The method sensitivity was calculated as per the formula given in 
the introductory part of analytical validation. The results for method 
sensitivity LOD and LOQ was found to be 0.28 µg/ml and 0.75 µg/ml. 
Assay 
The results obtained from the assay of the test and standard 
solutions in compliance with for original conditions. Assay of 20 
tablets of label claims 250 mg mean drug content and % RSD was 
found to be 98.02 % and 0.11 %. 
Accuracy 
The result of recovery studies at various levels shows that the 
recovery is between 99.52 to 100.13 % (limit 98-102 %). It indicates 
that there is no interference in the analysis of the drug from the 
excipients in the formulation. The results of recovery studies of the 
formulation are shown in table 1. 
Precision 
The Intraday and interday precision of sample applications and 
measurement of peak area for the drug were expressed in terms of 
% relative standard deviation (% RSD). For the inter-day variation 
studies, 3 replicates of standard solutions were analyzed on 3 
consecutive days and percentage RSD were calculated. The results 
obtained for Intraday and Inter-day variations are shown in table 2. 
Specificity 
For the evaluation of the specificity of the RP-HPLC-PDA method, 
the stress degraded standard solution was injected into RP-HPLC 
under the proposed chromatographic conditions overlay 
chromatogram for mobile phase-A, placebo-B, Standard-C and 
formulation–D is shown in fig. 3 (b). Procedures for degradation 
studies were described in material and method part of forced 
degradation study. 
 The chromatograms of ABA of various degradation conditions are 
shown in fig. 4, 5, 6, 7, 8, and 9. ABA most degraded in base 
degradation and degradants observed at a retention time (tR
 
) 4.10, 
4.79, 6.24, 7.19 min. In acidic, oxidative, UV, thermal and neutral 
minor degradation observed. The above results showed that the 
developed RP-HPLC-PDA method was specific for the determination 
of ABA in pharmaceutical preparations. A summary of degradation 
of ABA is shown in table 3 [7, 8]. 
Table 1: Accuracy study data 









R. S. D 
80% 7.5 5 12.5 12.44 99.20% 0.19 
100% 7.5 7.5 15 15.02 100.26% 0.23 
120% 7.5 1 17.5 17.46 99.46% 0.12 
 
Table 2: Interday and Intraday precision of ABA (n=3) 
Standard 
Conc. 
Intraday precision Interday precision 
10 µg/ml 15 µg/ml 20 µg/ml 10 µg/ml 15 µg/ml 20 µg/ml 
Replicates Peak area 
1 346958 536587 718467 346901 535946 718276 
2 348823 535688 721361 348823 534913 721569 
3 347894 534639 719684 347821 536284 719275 
Mean 347892 535638 719684 347848 535714 719706 
SD 932.5 974.9 1501.6 961.2 714.2 1688.4 
% RSD 0.26 0.18 0.20 0.27 0.13 0.23 
 
Acid degradation  
 
Fig. 4: Chromatogram of acid (1 M HCl for 5 h. at 45 °C) treated 
ABA tR-5.4, tR
 
–4.08 (D1), 7.20 (D4) min 
Base degradation  





 (D1), 4.79 (D2), 6.24 (D3), 7.21 (D4) min 
 






Fig. 7: Chromatogram of dry heat (24 h. at 45 °C) treated ABA tR 
5.4 min, tR–4.03, 4.83 min  
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Fig. 8: Chromatogram of photochemically (UV light, 12 h.) 








Table 3: Summary of degradation of ABA 
Stress condition % degraded Amount recovered Degraded products 
tR
Peak purity data (peak anglepeak 
threshold),  (min) 
1M HCL (5 h at 45o 4.65 % C) 95.35 % 4.08, 7.20 0.27, 1.34 
0.1M NaOH (5 h at 45o 10.08 % C) 89.92 % 4.09, 4.79, 6.24, 7.19 0.24, 1.32 
H2O2 (5 h at45o 0.94 % C) 99.06 % 4.82 0.28, 1.36 
Dry heat (24 h at 45o 3.97 % C) 96.03 % 4.03, 4.83 0.25, 1.31 
UV light (12 h) 1.08 % 98.92 % 4.80 0.23, 1.29 
Neutral (5 h at 45o 0.74 % C) 99.26 % 4.81 0.26, 1.33 
tR
 
 = Retention time, peak purity = Peak angle<peak threshold. 
 
Fig. 10: Mass spectra of base degradant D
 
Mass spectral analysis of base degraded product 
The mass spectral fragmentation pattern of the ABA shows a 
prominent molecular ion peak at m/e-391.5, which however is 
not the base peak. As shown in fig.10, under base hydrolysis lead 
to formation of degradant (D
2 
2 ) 10-Methyl 2,3,4,7,8,9,10,11,12, 
13,14,15-dodecanhydro-1H-cyclopenta (α) phenanthren-3-ol) at 
m/z-257.81, due to corresponding loss of C 8 H 12
The parameters included for observation of change level are 
temperature, flow rate, pH and wavelength. Each factor selected 
was changed at three levels (-1, 0, 1). One factor was changed at 
one time to estimate the effect. Results are given in table 4. In 
significantly less variability in retention times and peak areas 
were observed. 
Method stability 
 O N as shows in 
fig. 11 [9-11]. 
Robustness 
The result showed that both the retention time and the peak area of 
ABA were unchanged (% RSD less than 1.2 %) and no significant 
degradation was observed within 3 d which was sufficient for 
performing the analytical process. 
 
Fig. 11: Degradation pathway of ABA under base hydrolysis 
degradant (D2)
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Table 4: Robustness study data (n=3) 
Parameter count Change level Area Retention time (min % Assay, % RSD 
Temperature (40±2 o 38 °C C) 536710 5.40 100.19 %, 0.15 % 
42 °C 541218 5.42 101.02 % 0.12 % 
Flow rate (0.6±0.1 ml/min) 0.5 ml/min 535769 5.48 100.02 % 0.18 % 
0.7 ml/min 532359 5.31 99.39 %, 0.37 % 
PH 
(3.5±0.2) 
3.3 543057 5.46 101.36 %, 0.12 % 
3.7 535029 5.41 99.88 %, 0.87 % 
Wavelength 
(235±2 nm) 
233 531811 5.38 99.8 %, 0.25 % 
237 543984 5.42 99.69 %, 0.19 % 
 
DISCUSSION 
New RP-HPLC-PDA method was developed and validated for ABA. 
Various chromatographic conditions were tried during method 
development. Method was validated for linearity, accuracy, 
precision, specificity, LOD, LOQ and robustness these parameters. To 
make the method more specific stress degradation of API was 
carried out using acid, alkali, oxidative, thermal, UV light and neutral 
stress conditions. As per ICH guidelines 10-30 % stress limit is 
acceptable. All these conditions sufficient for separation of the 
degraded product were shown. Further analyte peak was pure as 
shown by peak purity study. The method is linear within the 
concentration range 5-30 μg/ml as represented by the value of 
correlation coefficient (r2) 0.991 and value of slope were less than 5 
% value of the area of nominal concentration. The method is accurate 
as shown by the result of recovery study % recovery (100±2) and % 
RSD (<2) values were found within the limit. Robustness study 
indicate that there is not much variation in system suitability test 
(SST) parameters and % assay of analyte (limit 100±2 %) under 
planned variation chromatographic study parameter retention time 
(tR), area, plate count (N), capacity factor (K´) and USP tailing were not 
considered for this study as these parameters were unaffected due to 
small chromatographic parameter variation as observed during 
development study. Degradation study shows that drug is more 
sensitive to alkali stress degradation. From mass spectral study the 
structure of one of the degraded base product was predicted which is 
major degradation product among all stress degraded products. The 
information is used to predict the alkali stress degradation pathway.  
CONCLUSION 
The results of the various validation studies showed that the RP-
HPLC-PDA method is fast, specific, accurate, reproducible, possessed 
optimum linearity and precision. A stability indicating method was 
developed which separated all degradation products formed under 
different stress conditions and degradation pathway of ABA under 
basic hydrolysis are suggested. In base hydrolysis the major base 
degradation lead to the formation of the degradation product eluted 
at tR-4.79 (D2) which was then determined by LC-MS at a m/z value 
of 257.81, due to corresponding loss of C8 H12 
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